Method for reducing pericardial fibrosis and adhesion formation
AssigneeNovartis AG
InventorsFrancis G. Spinale, Marc de Gasparo
Life of this patent
Estimating the term…
Abstract
Disclosed are methods of reducing fibrosis and adhesion formation in a surgical patient wherein the AT1 receptor antagonist, the compound (S)-N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine (valsartan) of formula or a salt thereof, in particular a pharmaceutically acceptable salt thereof, is administered to the patient. In particular, disclosed are methods of reducing pericardial fibrosis and pericardial adhesion formation which results from cardiac surgery.
Claims10
A method for reducing fibrosis and adhesion formations in a surgical patient comprising administering a therapeutically effective amount of valsartan prior to fibrosis and adhesion formation.
A method for reducing pericardial fibrosis and adhesion formations in a cardiac surgery patient comprising administering a therapeutically effective amount of valsartan prior to fibrosis and adhesion formation.
A method for reducing fibrosis and adhesion formations in a patient with an induced pathological condition selected from the group consisting of drug-induced retroperitoneal fibrosis, post irradiation fibrosis, peritonitis and post-toxic peritonitis adhesiolysis comprising administering a therapeutically effective amount of valsartan prior to fibrosis and adhesion formation.
Dependencies are inferred from the claim text.